The German drugmaker plans to advance the NSCLC treatment in parallel with tissue-based and liquid biopsy companion assays that can identify best responders.
The reagents involved in the deal improve the specificity and fidelity of PCR reactions.
The two companies have signed a new master collaboration agreement under which HTG will develop custom assays for use in earlier stages of Merck's drug development process.
The tests were developed as part of a partnership with Merck KGaA, one of the manufacturers of the anti-EGFR therapy Erbitux.
Guardant is providing its Guardant 360 CDx test for a clinical trial of Merck's small molecule, c-Met kinase inhibitor called tepotinib.
The companies are aiming to identify treatment-response biomarker signatures in patients with advanced melanoma.
The company said its proxy-CRISPR tool can facilitate precise gene editing and eliminates the need for genetic engineering of naturally occurring CRISPR proteins.
The moves underscore a growing belief in industry and academia that the cell-derived vesicles could be the biomarker of choice for next-generation tests and therapies.
The Merck KGaA subsidiary is launching the research-use only SMCxPRO later this year for protein detection using sandwich ELISAs paired with proprietary optical readout.
The company signed separate agreements with AstraZeneca, Merck, Merck KGaA, and Pfizer to create the panel, which is expected to help speed drug development.
In a commentary at eLife, Brandeis University's Eve Marder calls on researchers to value and pursue truth.
Researchers have developed a way to quickly edit white blood cells, according to the New York Times.
In Science this week: rice gene enables plants to grow quickly in times of flooding, and more.
Education-linked genetic variants could also predict a small portion of a person's social mobility, Newsweek reports.